Foghorn and Lilly halt FHD-909 program, company cuts 40% of workforce
Foghorn Therapeutics said it will not advance FHD-909 with Eli Lilly into expansion after Phase 1 data, and is reducing staff to focus on its own pipeline.
SEC filing
Latest
43 stories
Today
Tuesday, September 29
Altimmune names Richard Menziuso as principal accounting officer
The appointment, effective September 29, 2026, keeps Gregory Weaver as chief financial officer.
SEC filing
Lilly posts Lyumjev safety results in India; registers new Alzheimer's Phase 1 study
Friday, September 25
FDA approves efficacy supplement for Eli Lilly's Olumiant (baricitinib)
The FDA cleared a ninth supplemental application for Olumiant under a standard review, with the approval recorded on September 25, 2026.
Drugs@FDA
Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials update
Wednesday, September 23
FDA approves Eli Lilly's Onswik, a new insulin efsitora alfa-gobe injection
The agency's drug database lists the original biologics license application as approved with a status date of September 23, 2026.
Drugs@FDA
ProQR names Chris Hart as Chief Data and AI Officer, adds Thomas Wolf to board
The moves are meant to expand AI use across ProQR's Axiomer RNA editing programs, with an early readout for lead AI-discovered candidate AX-0811 expected in January 2027.
SEC filing
Friday, September 18
FDA approves new efficacy supplement for Eli Lilly's Verzenio
The regulator cleared supplement 22 for the abemaciclib tablet application on September 18, 2026, with updated labeling issued days later.
Drugs@FDA
FDA approves supplemental application for Eli Lilly's Inluriyo
The efficacy supplement for imlunestrant tosylate tablets received FDA approval, with a status date of September 18, 2026.
Drugs@FDA
Lilly's orforglipron posts Phase 3 diabetes results; six new trials registered
Tuesday, September 15
LB Pharmaceuticals names Susan Kozauer as chief medical officer
The neuromedicines company said the hire comes as it heads toward Phase 3 NOVA-2 schizophrenia trial results in the first half of 2027.
SEC filing
Friday, September 11
Lilly registers three new early trials: olomorasib in colorectal cancer, two obesity studies
Tuesday, September 8
Kura Oncology names Jennifer Fulk as chief financial officer
Fulk takes over principal financial and accounting officer duties effective September 8, 2026, under an employment agreement with severance terms tied to a change of control.
SEC filing
Friday, September 4
Lilly posts Phase 3 orforglipron results; two more programs report terminated-trial data
Thursday, September 3
Vaxcyte names new chief medical and legal officers, moves up OPUS-1 data timing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing
Thursday, August 27
FDA approves two efficacy supplements for Eli Lilly's Mounjaro
The agency cleared supplement numbers 44 and 45 for tirzepatide's NDA on the same status date, with labeling updated in early September 2026.
Drugs@FDA (2)
Lilly registers four new trials: Alzheimer's, cardiovascular, obesity, Crohn's programs
Wednesday, August 26
FDA approves efficacy supplement for Lilly's Zepbound (tirzepatide)
The agency signed off on submission 41 for NDA217806, with a corrected approval letter and label dated September 10, 2026.
Drugs@FDA
Thursday, August 20
Lilly registers Phase 3 depression trial; posts results for two psoriasis and oncology studies
Friday, August 14
Lilly posts orforglipron Phase 3 results; adds new early-phase studies
OPKO Health amends note agreement, issues $125 million in additional senior secured notes
The notes, tied to EirGen Pharma's mazdutide royalty interest from Eli Lilly, mature in 2044 and carry a SOFR-plus-7.5% rate with a 4% floor.
SEC filing
Thursday, August 13
ProQR reports Q2 2026 results, cites first Axiomer clinical validation from AX-0810 data
Tuesday, August 11
Absci reports Q2 2026 results, positive ABS-201 Phase 1 data, $100M raise with Lilly
Absci says its hair-loss antibody was well tolerated in early dosing, adds $40 million from Eli Lilly, and now expects cash to last into second half of 2028.
SEC filing
Monday, August 10
Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats
Belgium-based Agomab Therapeutics plans to add the two as non-executive directors, pending a shareholder vote in September 2026.
SEC filing
Friday, August 7
Entera Bio reports Q2 2026 results, cites FDA alignment on EB613 Phase 3 design
Entera raised $275 million in a private placement led by BVF Partners to fund a registrational Phase 3 trial of its oral osteoporosis drug EB613 through NDA submission.
SEC filing
Thursday, August 6
Amphastar hits BAQSIMI sales milestone, triggering $100 million payment to Lilly
The Q2 2026 filing discloses a $100 million payment due to Eli Lilly in Q3 2026 after BAQSIMI sales crossed a contract threshold, alongside new pipeline detail and an April ipratropium bromide launch.
SEC filing
Foghorn reports Q2 2026 results, FHD-909 trial on track with Lilly
Foghorn Therapeutics posted narrower Q2 losses and $167.6 million in cash as its lead SMARCA2 inhibitor advances in Phase 1 dose escalation for NSCLC.
SEC filing
VivoSim regains Nasdaq equity compliance, discloses post-10-K cash inflows
San Diego based VivoSim said Nasdaq confirmed it meets the $2.5 million stockholders' equity rule, while new milestone cash and a warrant financing lifted its cash position to $10.1 million.
SEC filing
Wednesday, August 5
Charles River raises 2026 guidance on stronger DSA and Manufacturing performance
The contract research firm posted a GAAP loss per share in the second quarter but lifted its full-year revenue and non-GAAP EPS outlook after book-to-bill improved.
SEC filing
Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growth
Second-quarter revenue rose 48% to $23.0 billion as Lilly reported progress across its obesity, immunology, and oncology pipeline.
SEC filing
Tuesday, August 4
iBio names endocrinologist Molly Carr as chief medical officer
The clinical-stage biotech hired the former Eli Lilly insulin executive effective July 31, 2026, and granted her 430,000 inducement stock options.
SEC filing
Lilly wins two label supplements: orforglipron tablet and teriparatide solution
Monday, August 3
Ascentage Pharma names new Chief Business Officer and Chief Commercial Officer
The company appointed Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO on August 2, 2026, dividing global deal-making from U.S. and ex-China commercial duties.
SEC filing
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial starts
FDA cleared CASGEVY for children as young as 2, and the company began Phase 1 trials for CTX340 and CTX460 while cash stood at $2,364.4 million.
SEC filing
Friday, July 31
Lilly-linked tirzepatide alopecia trial joins mazisotine results, eloralintide recruiting
Vistagen adds Douglas J. Williamson to board of directors
The neuroscience drug development veteran joins as Vistagen advances its pherine pipeline, including Phase 3 fasedienol for social anxiety disorder.
SEC filing
Monday, July 27
Precision BioSciences promotes CFO to COO, names new CFO effective August 1
The Board approved the executive changes on July 23, 2026, and the company announced them in a press release on July 27, 2026.
SEC filing
Monday, July 20
Lilly completes Phase 3 ATTAIN-J trial of oral orforglipron in Japanese obesity patients
Friday, July 17
Lilly posts results for five completed Phase 1 studies, opens three new early trials
Tuesday, July 14
FDA approves supplement 7 for Eli Lilly's Retevmo (selpercatinib)
The agency cleared an efficacy-related labeling update for the RET inhibitor, with a new label dated July 29, 2026.
Drugs@FDA
FDA approves efficacy supplement for Eli Lilly's Retevmo (selpercatinib)
The agency signed off on supplement 17 to Retevmo's original approval, with a new label dated July 29, 2026.
Drugs@FDA, SEC filing (2)
Monday, July 13
FDA approves efficacy-related supplement for Eli Lilly's Verzenio
The agency approved supplement 21 for the abemaciclib tablet, an efficacy-type submission, with the approval dated July 13, 2026.
Drugs@FDA